Trial Profile

The Neat-HER Virtual Registry: A novel registry following HER2+ ESBC patients receiving neratinib in the extended adjuvant setting

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Neratinib (Primary)
Indications Early breast cancer
Focus Therapeutic Use

Most Recent Events

08 Jun 2021 Updates results (n=33; data cutoff date December 2018) of the the Neat-HER virtual registry, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
03 Jun 2019 New trial record
31 May 2019 Results assessing information on clinical history and treatment patterns in a real-world cohort of patients published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com